Recent clinical trials using stem cells to reverse or slow down normal aging processes
The stem cells are the undifferentiated, pluripotent cells that can multiply indefinitely, or differentiate to progenitor and differentiated cells at end-phase (Slack, 2021). The inner cell mass (hE) of the blastocyst contains human embryonic stem cells (hESCs); h ESC research is fraught with ethical issues (Lo & Parham, 2009); and h ESC transplantation can cause large tumors known as teratomas.
In some \”niches\” of the organs, such as in the bone marrow where hematopoietic stem cells (HSC) replenish blood and immunity cells, SCs can be found. In 1958, Mathe et al. In 1959, five workers at the Vinca Nuclear Institute (Yugoslavia) who were exposed to high-dose accidental radiation successfully underwent the first adult SC treatment. All workers survived after transfusions and grafts with homologous adult marrow (Mathe, et. al., 1958).
The human umbilical chord was considered a waste product for many years. Its use, unlike that of h ESCs, does not raise any ethical issues. In 1988, Gluckman et al. In 1989, the first cord blood transplant was successfully performed on a child suffering from Fanconi anemia. Since then, many public and private cord-blood banks have been set up worldwide to cryopreserve cord blood for transplantation.
Source:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116573/
